Drug intelligence / Profile preview

IB001

Development stage: Preclinical
Lead developer: Intrepida Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IB001 is a lead candidate anti-BAG3 antibody developed by Intrepida Bio for the treatment of cancer, specifically pancreatic ductal adenocarcinoma (PDAC). The technology, targeting BAG3 and its receptor IFITM-2, was discovered at the University of Salerno and in-licensed by Intrepida Bio from Biouniversa s.r.l. Intrepida Bio launched in October 2019 with a $9.5 million equity investment to fund IND-enabling studies for IB001, with a goal to initiate clinical trials in 2021.

Targets

IFITM2 (Interferon-induced transmembrane protein 2)BAG3 (Bcl2-associated athanogene 3)

Beyond the preview

Go deeper on IB001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB001.

Explore the full profile